Trial reportBritish journal of cancer2019
Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.
Trial report in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Trial
- Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials.British journal of cancer · 2025Article
- Article
- Efficacy and safety of oral 5-FU-based adjuvant chemotherapy for geriatric patients with colorectal cancer: Integrated analysis of seven clinical trials conducted at the Japanese Foundation for Multidisciplinary Treatment of Cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2025Article
- Recurrence Timing and Risk Following Curative Resection of Colorectal Liver Metastases: Insights From a Hazard Function Analysis.Journal of surgical oncology · 2025Article
- Personalizing adjuvant therapy for patients with colorectal cancer.Nature reviews. Clinical oncology · 2024Review
- The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival.International journal of clinical oncology · 2023Article
- Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database.Current oncology (Toronto, Ont.) · 2023Article
- Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer.BMC cancer · 2022Article
- Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies.Current oncology (Toronto, Ont.) · 2021Article
- Postoperative Nutritional Status is Predictive of the Survival Outcomes in Patients Undergoing Resection of Stage III Colorectal Cancer.World journal of surgery · 2021Article
- Article
- The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients.International journal of clinical oncology · 2021Article
- Recurrence hazard of rectal cancer compared with colon cancer by adjuvant chemotherapy status: a nationwide study in Japan.Journal of gastroenterology · 2021Article
- Dealing with pre-existing chronic neutropenia in cancer patients-considerations and consequences in the clinical praxis.Ecancermedicalscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUp to 6-months oxaliplatin-containing regimen is now widely accepted as a standard adjuvant chemotherapy for stage III colorectal cancer (CRC). However, oral fluoropyrimidine monotherapy is used for some part of patients, especially in Asian countries including Japan, and its optimal duration is yet to be fully investigated.
methodsA total of 1306 patients with curatively-resected stage III CRC were randomly assigned to receive capecitabine (2500 mg/m
resultsThe 3- and 5-year DFS were 70.0% and 65.3% in the 6M group and 75.3% and 68.7% in the 12M group, respectively (p = 0.0549, HR = 0.858, 90% CI: 0.732-1.004). The 5-year RFS was 69.3% and 74.1% in the 6M and 12M groups, respectively (p = 0.0143, HR = 0.796, 90% CI: 0.670-0.945). The 5-year OS was 83.2% and 87.6%, respectively (p = 0.0124, HR = 0.727, 90% CI: 0.575-0.919). The incidence of overall grade 3-4 adverse events was almost comparable in both groups.
conclusionsAlthough 12-month adjuvant capecitabine did not demonstrate superior DFS to that of 6-month, the observed better RFS and OS in the 12-month treatment period could be of value in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.